Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

A Phase 2A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Immune Response, Safety and Efficacy of HS-110 in Combination With Erlotinib vs. Erlotinib as a Single Agent in Patients With Advanced, Non-EGFR Mutated Non-Small Cell Lung Cancer (NSCLC)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT01504542
• Other study ID #: HS110-10-01
• Status: Withdrawn
• Phase: Phase 2
• First received: December 20, 2011
• Last updated: November 20, 2013
• Start date: December 2011
• Est. completion date: December 2013

Study information

• Verified date: November 2013
• Source: Heat Biologics
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

This study will enroll patients with locally advanced or metastatic non-EGFR mutated Non-Small Cell Lung Cancer (NSCLC) lung cancer after failure of at least one but no more than two prior approved treatment regimens. Patients will be randomized to receive one of two doses of vaccine or placebo to be dosed twice weekly for 18 weeks (36 doses total) and patients will also receive erlotinib 150mg taken orally once daily for the duration of the trial. The study will examine the immune effects, safety and efficacy of two different doses of HS110 vaccine in combination with erlotinib versus erlotinib alone.

Description:

This multicenter, randomized, double-blind, placebo-controlled study will enroll patients with advanced NSCLC (squamous cell or non-squamous cell) without EGFR mutations (either L858R or 746-750 deletions) who have had progression or recurrence of their disease following at least one but no more than two prior regimens (adjuvant therapy excluded) of approved therapy that did not include immunomodulating or anti-EGFR targeted therapy for their disease. EFGR status must be known at the time of enrollment either via prior determination or testing performed from archival tissue during the screening process. Patients with resectable disease will eligible if resection can be deferred for the first six weeks of vaccine. Patients will receive twice weekly dosing of vaccine (spatially divided as 5 intradermal injections) for 18 weeks (36 total doses). Patients will be randomized in a 2:1 fashion; with 30 patients in each of the HS110 treatments groups (high and low dose) and 15 patients will receive placebo injections. Patients will also receive erlotinib 150mg once daily for the duration of the trial. A total of 75 patients will be enrolled in the trial. The study includes a lead-in phase of 9 patients (3 from each dosing group) who will be observed weekly for 4 weeks to assess the safety of combining HS110 with erlotinib. Treatment of the first 4 patients will be staggered by 2 week intervals to allow for safety evaluation before treating additional patients. If the combination of proves to be safe and well-tolerated in the first 9 patients, enrollment will be opened up to the predetermined sample size for each arm. A Data Monitoring Committee (DMC) will be used in this study to independently monitor adverse events and progression/survival data. The DMC will meet at the completion of the run-in period and after half the patients have been dosed through week 6 and week 12.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2013
• Est. primary completion date: December 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing and able to comply with the protocol and sign informed consent.

• Histologically or cytologically confirmed locally advanced or metastatic squamous cell or non-squamous cell NSCLC after at least one but no more than two prior regimens of approved therapy for their disease (not including adjuvant treatment).

• Confirmation that their disease has no known EGFR mutations based on documented prior analysis or study-specific analysis of archival tumor tissue.

• At least one site of bi-dimensionally measurable NSCLC disease.

• Patients with recurrent, resectable disease able to undergo six weeks of vaccine therapy prior to resection.

• Brain metastasis if present and treated must be stable by CT scn or MRI for at least 8 weeks.

• Age = 18 years.

• EGOG performance status of 0-1.

• Lab parameters

• Albumin = 3.5mg/dL

• Total Bilirubin < 1.5mg/dL

• Alanine transaminase (ALT), and aspartate transaminase(AST)= 2.5 x upper limits of normal or = x ULN in case of liver metastases.

• Serum creatinine < 1.5mg/dL or calculated creatinine clearance >50 mL/minute per the Cockcroft-Gault formula.

• White blood cell (WBC) count = 4,000/mm3 with an absolute neutrophil count

• 1,500mm3.

• Hemoglobin = 9g/dL

• Platelet count = 100,000/mm3

• Women of childbearing potential or men of fathering potential must use adequate birth control measures (e.g. abstinence, oral contraceptives, intrauterine device, barrier method with spermicide or surgical sterilization) during the study and for 6 months after receiving the last administration of study medication. Female patients of childbearing potential must test negative for pregnancy prior to enrolling in the trial. Post-menopausal (cessation of menses for more than 6 months) women are eligible for this study.

Exclusion Criteria:

• No prior therapy with EGFR-targeted drugs, including approved and investigational therapies, or prior immunologic or biologic response modifier therapy for treatment of their disease.

• Uncontrolled or untreated brain or spinal cord metastases or meningeal carcinomatosis.

• Known human immunodeficiency virus (HIV), hepatitis B or C, or severe/uncontrolled infections or intercurrent illness, unrelated to the tumor, requiring active therapy.

• Autoimmunity syndromes (primary or acquired) including, but not limited to, the following: rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, or glomerulonephritis requiring active steroid or other immunosuppressive therapy.

• Known immunodeficiency disorders, either primary or acquired.

• Other malignancies present within the past 3 years, except for cutaneous basal and/or squamous cell carcinoma(s) or in situ cervical cancer.

• History of clinically significant cardiac impairment, congestive heart failure > New York Heart Association (NYHA) cardiac disease classification Class II, unstable angina, or myocardial infarction during the previous 6 months, or serious cardiac arrhythmia.

• Known alcohol or chemical abuse, or mental or psychiatric condition precluding compliance with the protocol.

• Chemotherapy, radiation, or other antitumor therapy during the last 4 weeks.

• Pregnant, nursing, or planning a pregnancy (both men and women) within 12 months of enrollment.

• Known allergy to soy or egg products.

• Patient is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Biological:
• HS110 vaccine
0.5ml to be administered twice weekly for 18 weeks (36 doses)
• Placebo
0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
• HS110 vaccine
0.5 mls to be dosed twice weekly for 18 weeks (36 doses)

Locations

Country	Name	City	State
United States	Mary Crowley Cancer Research Centers	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Heat Biologics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Immunologic Response (defined as production of IFN? from CD8+ T cells as evaluated by ELISPOT assay)	Immune response will be evalulated by ELISPOT assays and change will be assessed from baseline.	Week 18	No
Secondary	Safety of the combination of HS110 vaccine and erlotinib	Incidence and severity of adverse events, changes in laboratory measures, physical exams and evaluation of autoimmune phenomena.	Up to 1 year	Yes
Secondary	Tumor assessment by immunologic response criteria (irRC)	Patients will have a CT scan performed at baseline, Week 12 and Week 22 or at the end of study visit in the case of early termination from study. Investigators will assess the disease response using irRC for overall response, CR, PR, SD or PD.	Baseline, Week 12 and Week 22	No
Secondary	Exploratory Immunologic endpoint - evaluation of circulating tumor cells	Analysis via a semiautomated, epithelial cell adhesion molecule-based immunomagnetic technique.	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18	No
Secondary	Exploratory immunologic endpoint - immune function	Analysis of cell surfance molecules by flow cytometry	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18	No
Secondary	Exploratory immunologic endpoint - proteomic profile	Examination of protein expression utilizing western blot, immunohistochemical staining, enzyme linked immunosorbent assay (ELISA) or mass spectrometry	Baseline, Week 1, Week 2, Week 3, Week 4, Week 6, Week 9, Week 12 and Week 18	No